Table 2.

Mean Levels of Markers at Baseline and 3, 6, and 12 Months by Treatment Arm

	Baseline (Month 0)			Month 3			Month 6			Month 12
Marker	CPT	Placebo	P Value	CPT	Placebo	P Value	CPT	Placebo	P Value	CPT	Placebo	P Value
LPS, EU/mL	1.22a	0.28	.087	0.20	0.22	.397	1.21	1.16	.232	1.17	1.21	.261
TNF-α, pg/mL	2.18	2.10	.792	2.20	2.77	.088	2.97	3.56	.219	2.83	3.56	.119
sCD14, pg/mL	1 595 982	1 599 178	.850	1 672 784	1 776 223	.168	1 830 318	1 758 550	.310	1 953 240	1 966 961	.876
IL-6, pg/mL	2.74	3.04	.205	2.61	3.96	.001	2.71	3.26	.082	2.88	3.45	.045
EndoCAb IgM	49.40	46.06	.455	51.94	45.60	.103	47.94	43.82	.312	52.46	45.15	.109
IFABP, pg/mL	1118.79	1236.45	.268	1225.37	1230.28	.918	1155.17	1151.71	0.977	1118.79	1176.15	.567
CRP, ng/mL	1088.98	1649.12	.036	1327.43	2418.74	.001	1198.71	1694.26	0.108	1176.15	1872.44	.023
CD4+ CD38+ HLA-DR+, %b	0.22	0.25	.559	0.22	0.26	.330	0.21	0.23	0.568	0.56	0.57	.836
CD8+ CD38+ HLA-DR+, %b	0.37	0.45	.399	0.42	0.43	.929	0.25	0.38	0.023	0.75	0.85	.508

P values of the t test comparing CPT to placebo arm for each log-transformed marker at each month of follow-up. Values in bold are statistically significant.

Abbreviations: CPT, cotrimoxazole preventive therapy; CRP, C-reactive protein; EndoCAb, anti-endotoxin core antibody; IFABP, intestinal fatty acid binding protein; IgM, immunoglobulin M; IL-6, interleukin 6; LPS, lipopolysaccharide; sCD14, soluble CD14; TNF-α, tumor necrosis factor alpha.

^aMean (reverse log transformed).

^bMarker not transformed on logarithm scale and indicates activation levels.